News

July 22, 2017July 23, 2017

COX-2 Inhibitors May Improve Cancer Immunotherapy Response

A new study shows that tumors that constantly express the protein IDO1 (indoleamine 2,3-dioxygenase) are sensitive to COX-2 inhibitors, which may provide an increase in T-cell anti-tumor function. The ... Read more

July 21, 2017July 21, 2017

Opdivo, Yervoy, and Keytruda May Induce Rare Adverse Reactions Affecting the Eye, FDA Says

News

The U.S. Food and Drug Administration (FDA) is considering adding the risk of eye toxicities that could cause vision loss and retinal detachment on the labels of Bristol-Myers Squibb’s Opdivo ... Read more

July 20, 2017

NT-219 Re-sensitizes Cancer to Keytruda, Stopping Tumor Progression, Study Shows

News

Adding TyrNovo‘s NT-219 to Merck’s Keytruda (pembrolizumab) converted Keytruda-resistant tumors into therapy responders, stopping tumor progression, a study reports. The research, which involved a number of cancers, was a collaboration between Bar Ilan University and ... Read more

July 19, 2017

Opdivo Extends Survival, Has Less Impact on Lives in Head and Neck Cancer Patients Than Standard Chemo, Study Shows

News

The immunotherapy Opdivo (nivolumab) is less aggressive than standard-of-care chemotherapy for patients with recurrent or metastatic head and neck cancer, and has less of an impact on patients’ quality ... Read more

July 18, 2017July 18, 2017

Celgene Working with BeiGene to Develop Its PD-1 Inhibitor, BGB-A317, to Treat Solid Tumors

News

Celgene Corporation has entered a strategic collaboration with BeiGene to develop and commercialize its PD-1 inhibitor BGB-A317, an immunotherapy primarily aimed at treating solid tumors, in the U.S., Europe, Japan and much of the ... Read more

July 17, 2017

Phase 3 Trial to Assess Cabometyx Combo Therapies vs. Sutent in Advanced Kidney Cancer Patients

News

Exelixis and Bristol-Myers Squibb are starting a Phase 3 trial called CheckMate 9ER to assess Cabometyx (cabozantinib) in combination with immune checkpoint inhibitors in patients with newly-diagnosed advanced renal cell carcinoma, ... Read more

July 14, 2017

PDS, Merck to Launch Trial Testing Combo Therapy in Treating Certain Head and Neck Cancer Patients

News

PDS Biotechnology Corporation and a subsidiary of Merck are collaborating to develop a Phase 2 clinical trial for a combination cancer treatment for people with certain types of head and ... Read more

July 13, 2017

$3.75 Million in Grants to Help ViraCyte Continue Working on Therapies to Combat Post-transplant Viruses

News

ViraCyte has received a combined $3.75 million from the National Institutes of Health and the U.S. Food and Drug Administration to continue developing T-cell immunotherapies for viruses associated with ... Read more

July 12, 2017

Gene Expression Analysis Helps Determine Sensitivity to Immunotherapies

News

Researchers at Johns Hopkins University have discovered that variations in gene expression levels can provide insight into mechanisms that allow tumors to respond to immunotherapies. The study, “Transcriptional Mechanisms ... Read more

July 11, 2017

Mirati Hosts Key Opinion Leader Breakfast on Immuno-oncology Combinations in NYC

News

Mirati Therapeutics hosted a key opinion leader breakfast on immuno-oncology combinations on July 11 in New York City, the company announced in a press release. Featured at the breakfast were presentations ... Read more